Scandion Oncology A/S

Chart & Performance

D1W1MN

No data to show

P/E

—

P/S

—

EPS

—

Div Yield, %

—

Shrs. gr., 5y

31.76%

Rev. gr., 5y

Revenues

Net income

-39m

L-48.89%

CFO

-51m

L-27.04%

Earnings

May 20, 2025

Profile

Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company's other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors. Scandion Oncology A/S was founded in 2017 and is headquartered in Copenhagen, Denmark.

URL

https://scandiononcology.com/

IPO date

Nov 08, 2018

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title DKK in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title DKK in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12
Income
Revenues
Cost of revenue	45,803	72,076
Unusual Expense (Income)
NOPBT	(45,803)	(72,076)
NOPBT Margin
Operating Taxes	5,500	(5,500)
Tax Rate
NOPAT	(51,303)	(66,576)
Net income	(39,204) -48.89%	(76,700) 48.34%
Dividends
Dividend yield
Proceeds from repurchase of equity		53,545
BB yield
Debt
Debt current	499	776
Long-term debt	499	2,418
Deferred revenue
Other long-term liabilities		(1,000)
Net debt	(25,522)	(74,411)
Cash flow
Cash from operating activities	(50,668)	(69,443)
CAPEX		(414)
Cash from investing activities	288	(389)
Cash from financing activities	(705)	41,727
FCF	(53,901)	(67,231)
Balance
Cash	26,520	77,605
Long term investments
Excess cash	26,520	77,605
Stockholders' equity	(201,886)	(162,681)
Invested Capital	233,507	234,604
ROIC
ROCE
EV
Common stock shares outstanding	40,707	42,928
Price
Market cap
EV
EBITDA	(44,834)	(71,194)
EV/EBITDA
Interest		495
Interest/NOPBT